Wolfgang Miesbach: How to Better Understand and Explain Gene Therapy of Haemophilia?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“How to better understand and explain gene therapy of haemophilia? Our latest publication, ‘Gene-based therapies for hemophilia,’ is now available as full-open access article in Research and Practice in Thrombosis and Haemostasis! This illustrated review provides a comprehensive overview of gene therapy for hemophilia A and B, highlighting how recent advances are transforming patient care.
Through 10 detailed figures, the article breaks down complex concepts into clear visuals, making it easier for both patients and healthcare professionals (HCPs) to understand:
· Mechanisms of gene therapy: How adeno-associated virus (AAV) vectors deliver functional FVIII or FIX genes to address the root cause of hemophilia
· Clinical outcomes: Visual summaries of trial results for therapies like valoctocogene roxaparvovec, etranacogene dezaparvovec, and fidanacogene elaparvovec, showing sustained factor production and reduced bleeding episodes
· Benefits for patients: Figures illustrate the potential for long-term freedom from regular infusions and improved quality of life
· Challenges and future directions: Visuals explain ongoing issues such as immune responses, hepatotoxicity, and strategies for expanding eligibility and durability
These figures are invaluable for:
· Educating patients about what gene therapy means for their treatment journey
· Empowering HCPs with up-to-date, evidence-based visuals to support informed discussions and shared decision-making
Read the full open-access article to explore all 10 figures and deepen your understanding of gene therapy’s promise for haemophilia patients.”
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 9, 2025, 14:11Join Dr. Bethany Samuelson Bannow for a Virtual Event on Hemostasis and Cancer
-
Jul 9, 2025, 13:59Late-Breaking Insights from ISTH 2025: Rurioctocog Alfa Pegol in PUPs with Hemophilia A
-
Jul 12, 2025, 15:337 Tesla MRI Sheds Light on END Mechanisms in Symptomatic MCA Stenosis
-
Jul 12, 2025, 15:221 in 100: Subclavian Steal Syndrome Revealed by LVO Stroke in Case with Persistent Trigeminal Artery
-
Jul 11, 2025, 18:50ICAS Not a Factor: Post-EVT Intensive BP Control within 24 hrs Worsens Outcomes
-
Jul 11, 2025, 17:57Need for Recanalization Strategies Reinforced in P1 and P2: PCA Stroke Poor Outcomes
-
Jul 11, 2025, 15:40Wolfgang Miesbach: How to Better Understand and Explain Gene Therapy of Haemophilia?
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025